Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$175.85 USD

175.85
51,635

-1.04 (-0.59%)

Updated Aug 6, 2025 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Mark Vickery headshot

Top Research Reports for Royal Dutch Shell, TOTAL & Becton, Dickinson

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Royal Dutch Shell (RDS.A), TOTAL (TOT) and Becton, Dickinson (BDX).

Zacks Equity Research

Becton Dickinson (BDX) Up 2.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold on to Becton, Dickinson Stock Now

by Zacks Equity Research

Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.

Zacks Equity Research

BD's Onclarity HPV PMA Submission to Boost Women's Health

by Zacks Equity Research

Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.

Zacks Equity Research

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

by Zacks Equity Research

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Zacks Equity Research

Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.30% and 0.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

by Urmimala Biswas

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Zacks Equity Research

Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sreyoshi Mukherjee headshot

Dental Supplies Industry's Near-Term Outlook Looks Bright

by Sreyoshi Mukherjee

With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.

Zacks Equity Research

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

by Zacks Equity Research

Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.

Sreyoshi Mukherjee headshot

Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch

by Sreyoshi Mukherjee

As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.

Zacks Equity Research

Why Is Becton Dickinson (BDX) Up 4.1% Since Last Earnings Report?

by Zacks Equity Research

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

Mark Vickery headshot

Top Analyst Reports for Estee Lauder, Becton, Dickinson & Applied Materials

by Mark Vickery

Today's Research Daily features updated research reports on 16 major stocks, including Estee Lauder (EL), Becton, Dickinson (BDX) and Applied Materials (AMAT).

Zacks Equity Research

Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

Urmimala Biswas headshot

FDA Resets PAD Guidelines: The Road Ahead for Device Makers

by Urmimala Biswas

On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.

Zacks Equity Research

Cardiovascular Systems Set to Present LIBERTY 360 Outcome

by Zacks Equity Research

This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

Zacks Equity Research

China Arrests Yuan's Plunge. Will Markets Gain?

by Zacks Equity Research

China Arrests Yuan's Plunge. Will Markets Gain?

Zacks Equity Research

Stock Market News For Aug 6, 2019

by Zacks Equity Research

Benchmarks fell to their lowest levels for the year on Monday.

Zacks Equity Research

Index Futures Rebound as China Arrests Yuan Plunge

by Zacks Equity Research

U.S. stock index futures rebounded strongly ahead of trading on Tuesday after Chinese authorities acted to arrest the yuan???s decline.

Zacks Equity Research

Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues

by Zacks Equity Research

Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.

Zacks Equity Research

Becton Dickinson (BDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.98% and 0.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?

by Zacks Equity Research

Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.